Business Wire

WYSS-CENTER

29.9.2021 11:02:05 CEST | Business Wire | Press release

Share
Wyss Center Announces CE Mark for Its Brain Data Visualization Software, Epios Cloud

The Wyss Center announced today the CE (Conformité Européenne) mark Class I medical device for its Epios Cloud software. Epios Cloud is a web-based application for the online storage, processing and review of neural signals, including the ultra-long-term data recorded by an emerging generation of devices for remote brain monitoring. Its novel features allow seamless navigation of datasets covering months and years while access through a web browser allows clinicians to access patient data anywhere and anytime.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005365/en/

With the flexibility to connect to brain - or other bio-signal - recording devices over the web, Epios Cloud provides insights on multiple long-term data sources enabling clinicians to develop bespoke analytics to support personalized clinical decision making.

Clinicians are increasingly seeking options for outpatient neural monitoring over weeks to months. In epilepsy, home-based monitoring of brain activity during everyday life will help characterize the type and number of seizures, improve diagnosis and pre-surgical planning, and help build personalized treatment plans.

“We developed Epios Cloud as we needed software that would track not only when seizures occur but also the biosignals linked to epilepsy events. Epios Cloud allows us to synchronize neural data with heart rate or movement information over months or years. It gives us a glimpse of what is really going on in the brain during every-day life. In the future, additional data streams could easily be integrated into the platform to support other clinical applications. Importantly, centralized data storage will allow a fundamental change in automated analysis of neural data, allowing artificial intelligence algorithms to learn on an ever-growing global data lake – the development of which is already underway.” said Aleksander Sobolewski , PhD, Wyss Center Neuroscientist.

While current electroencephalogram (EEG) software is primarily optimized for the review of neural recordings that last minutes to hours, Epios Cloud is poised for the transition to longer-term recordings of weeks to months. Clinicians can also annotate the data with real-life events and develop novel analytics to automatically present regions of interest to complement visual screening.

George Kouvas , MBA, Wyss Center’s Chief Technology Officer said: “Epios Cloud is set to reveal new insights about epilepsy in individual patients – paving the way for personalized therapies. Now that Epios Cloud is CE marked, we look forward to connecting it to more brain recording modalities and to bringing this innovative long-term brain monitoring platform to more clinical or outpatient settings across Europe and beyond. Epios Cloud also has potential for use in stroke rehabilitation as well as neuromodulation of brain circuits for mental health applications.”

Epios Cloud is medical device software of Safety Class A as per IEC 62304 and CE-marked as Class I as per the Medical Device Directive 93/42/EEC. Epios Cloud is intended for displaying and reviewing electroencephalogram (EEG) recordings made by EEG devices using scalp and sub-scalp electrodes, heart rate and accelerometer measurements. The device is intended to be used by qualified medical practitioners. CE marking indicates that a product has been assessed and deemed to meet European Union safety, health and environmental protection requirements.

ENDS

About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland

The Wyss Center is an independent, non-profit research and development organization that advances our understanding of the brain to realize therapies and improve lives.

The Wyss Center staff, together with the Center’s academic, clinical and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroimaging and neurotechnology.

Wyss Center advances reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease to accelerate the development of devices and therapies for unmet medical needs.

The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.

www.wysscenter.ch/

Link:

ClickThru

Social Media:

https://www.facebook.com/wysscenter/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release

Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ

Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release

The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College

Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release

As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi

ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release

Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye